Voluntis (Paris:VTX) (Euronext Paris:VTX)(Mnemo:VTX) (ISIN:FR0004183960) on Wednesday announced its plans to enhance patient care coordination in immunology via innovative digital therapeutic software in collaboration with the research-based global biopharmaceutical company AbbVie.

Under the partnership, AbbVie will leverage Voluntis' proven Theraxium technology to make this new solution available to patients and providers in the US.

Through the Theraxium technology platform, Voluntis designs and operates multiple digital therapeutics, including Insulia and Diabeo in diabetes as well as eCO and ZEMY in oncology.

Based out of Boston and Paris, France, Voluntis creates digital therapeutics that empower people suffering from chronic conditions to self-manage ther treatment every day, thus improving real-world outcomes and is a founding member of the Digital Therapeutics Alliance.